DS
IOVA icon

David Shaw’s Iovance Biotherapeutics IOVA Stock Holding History

David Shaw’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-22,800
Closed -$183K – 4697
2024
Q2 		$183K Sell
22,800
-46,600
-67% -$499K ﹤0.01% 4091
2024
Q1 		$1.03M Buy
+69,400
New +$808K ﹤0.01% 3077
2020
Q3 		– Sell
-20,000
Closed -$549K – 3982
2020
Q2 		$549K Sell
20,000
-20,000
-50% -$658K ﹤0.01% 3302
2020
Q1 		$1.2M Buy
+40,000
New +$1.06M ﹤0.01% 2595

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

David Shaw's IOVA Position: Q2 2026 in Review

David Shaw reduced its Iovance Biotherapeutics (IOVA) stake by 73% in Q2 2026, selling an estimated $22.3M and leaving 2,143,134 shares worth $8.92M. The position accounts for ﹤0.01% of the portfolio, ranked #1921.

David Shaw first reported a position in IOVA in Q2 2015 and has held it in 32 quarters since. The position peaked at $34.9M in Q1 2024. 289 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • David Shaw held 2,143,134 shares of Iovance Biotherapeutics worth $8.92M as of Q2 2026.
  • David Shaw sold 5,873,219 Iovance Biotherapeutics shares in Q2 2026, an estimated $22.3M.
  • Iovance Biotherapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #1921 holding.
  • David Shaw first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 32 quarters since.
  • David Shaw's Iovance Biotherapeutics position peaked at $34.9M in Q1 2024.
  • 289 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.